New York, USA - November 10, 2010, New York, USA - Forest Laboratories, a pharmaceutical company, announced the retirement of Lawrence S. Olanoff, president and chief operating officer, effective December 31.
Article continues below
Dr. Olanoff has been President and Chief Operating Officer of the Company since October 2006. From July 2005 to October 2006, Dr. Olanoff served as President and Chief Executive Officer at Celsion Corporation where he was also a director from July 2005 to July 2006.
For ten years prior to July 2005, Dr. Olanoff served as Executive Vice President and Chief Science Officer at Forest. He will continue as a Director of the Corporation and will become Senior Scientific Advisor.
The company also announced several other executive management promotions. Elaine Hochberg, Senior Vice President and Forest's Chief Commercial Officer, who currently has responsibility for the Marketing and Managed Markets groups, has been promoted to Executive Vice President and Chief Commercial Officer and will be responsible in addition for the Trade and Institutional Sales Groups and the General Field Salesforce.
Ms. Hochberg joined Forest in 1997 as Vice President, Marketing, having prior served as Assistant Vice President of Marketing at Wyeth-Lederle Laboratories. She will continue to report to Howard Solomon.
Frank Perier, Jr., Senior Vice President Finance and Chief Financial officer, who currently manages the Finance, Treasury, Tax, Procurement, Risk Management and Investor Relations groups, has been promoted to Executive Vice President Finance and Administration and Chief Financial Officer.
Mr. Perier joined Forest in 2004 as Chief Financial Officer. For eight years prior, Mr. Perier served in various financial positions at Bristol-Myers Squibb including Vice President, Americas Medicine and Vice President, Finance, Planning and Business Development and Information Technology at its ConvaTec Division.
Prior to that, Mr. Perier had been a partner at Deloitte and Touche, LLP. He will report to Howard Solomon.
Dr. Marco Taglietti, Vice President Research and Development and President of the Forest Research Institute (FRI), has been promoted to Senior Vice President Research and Development and President, FRI, and will in addition be responsible for the Cerexa anti-infectives subsidiary.
Dr. Taglietti joined Forest in 2007 as Executive Vice President of the Forest Research Institute and Chief Medical Officer. Prior to that, he was Head of Global R&D at Stiefel Laboratories for three years and served for twelve years in various clinical management positions at Schering-Plough.
David Solomon, Vice President Business Development and Strategic Planning, has been promoted to Senior Vice President Corporate Development and Strategic Planning. He is presently responsible for the Business Development and Alliance Management groups, including our expanding North American and European operations. In addition, he will be responsible for the Informatics and Manufacturing Operations functions.
Kevin Walsh, Vice President Information Systems and Manufacturing Operations, has been promoted to Senior Vice President and Director of Operations. He is currently responsible for Information Systems and Manufacturing Operations, including all Supply Chain, Technology Transfer and Facilities Engineering functions and will, in addition, become responsible for Corporate Compliance.
Mr. Walsh joined Forest as Vice President, Information Systems, in 2003 having prior served as Vice President of Information Technology at Roche Pharmaceuticals.
Jerome Lynch, Senior Vice President Sales of Forest Pharmaceuticals, has been promoted to Senior Vice President Sales of Forest Laboratories. He presently is responsible for all Territory and Specialty Sales, and Sales Analytics and will, in addition, become responsible for Sales Training. ■